Sarah K. Lynam MD

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Sarah K. Lynam MD sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

Sarah K. Lynam MD: 1 sponsored US clinical trial, 1 recruiting.

Sarah K. Lynam MD sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Serous Ovarian Cancer, with 1 trials.

Mid-pack sponsor footprint

Sarah K. Lynam MD is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Phase Distribution

PhaseTrial count
Phase 2 1

Therapeutic Areas

What is open in the Sarah K. Lynam MD pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Serous Ovarian Cancer (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Sarah K. Lynam MD: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Sarah K. Lynam MD sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Sarah K. Lynam MD1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Sarah K. Lynam MD sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Sarah K. Lynam MD sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

What to do with this Sarah K. Lynam MD page

1 registered trials is a research-attention snapshot, not an endorsement of Sarah K. Lynam MD or any single study.

  • 1 of Sarah K. Lynam MD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Serous Ovarian Cancer is the condition Sarah K. Lynam MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Serous Ovarian Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Sarah K. Lynam MD pipeline card: 1 registered trials from official public datasets.Report a data error.